Suven Life Sciences Ltd. (SUVEN)

Overview

Suven Life Sciences Limited is a clinical-stage biopharmaceutical company with a focused vision on the discovery, development, and potential commercialization of novel therapeutic products. The company dedicates its resources to tackling neurodegenerative disorders, benefiting patients in India, the United States, Europe, and other international markets. Originally established as Suven Pharmaceuticals Pvt. Ltd., the firm underwent a rebranding to Suven Life Sciences Limited in 2003. With its foundation laid in 1989 and headquarters in Hyderabad, India, the company positions itself as a significant player in the neuropharmacological sector. As a subsidiary of Jasti Property and Equity Holdings Private Limited, Suven Life Sciences embarks on a journey to innovate in the realm of brain health by working on new chemical entities aimed at various central nervous system diseases.

Products and Services

The company's pipeline illustrates a promising range of products targeting different aspects of neurological and psychiatric disorders:

• Masupirdine (SUVN-502) - Developed for the treatment of Alzheimer’s disease and associated neuropsychiatric symptoms. This candidate demonstrates Suven’s approach to targeting neurodegenerative diseases at their core.
• Samelisant (SUVN-G3031) - As a histamine 3 receptor inverse agonist, this molecule is in the pipeline for addressing sleep and cognitive disorders. Its unique mechanism could offer a new avenue for therapy in sleep-related conditions.
• Ropanicant (SUVN-911) - This Alpha4Beta2 nAChRs receptor antagonist is being explored for its potential in treating depressive disorders, reflecting the company’s dedication to mental health innovations.
• Usmarapride (SUVN-D4010) - A potent, selective, orally bio-available, and brain penetrant 5-HT4 receptor partial agonist, Usmarapride targets cognitive disorders, highlighting the company’s focus on enhancing cognitive health among patients.
• SUVN-I6107 - Currently under development for cognitive disorders, this molecule adds to the company’s repertoire of cognitive health solutions.
• SUVN-M8036 - This candidate is being developed for the treatment of psychiatric disorders, further underlining Suven’s commitment to addressing comprehensive aspects of mental health.
• SUVN-D1044 - With a focus on gastrointestinal disorders, this product candidate illustrates the company’s expansive approach to healthcare, reaching beyond neurodegenerative and psychiatric diseases.